OAC
UNCY icon

OMERS Administration Corp’s Unicycive Therapeutics UNCY Stock Holding History

OMERS Administration Corp’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$210K Sell
31,900
-46,300
-59% -$303K ﹤0.01% 913
2025
Q4 		$451K Buy
+78,200
New +$417K ﹤0.01% 692

Other funds holding UNCY

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

OMERS Administration Corp's UNCY Position: Q1 2026 in Review

OMERS Administration Corp reduced its Unicycive Therapeutics (UNCY) stake by 59% in Q1 2026, selling an estimated $303K and leaving 31,900 shares worth $210K. The position accounts for ﹤0.01% of the portfolio, ranked #913.

OMERS Administration Corp first reported a position in UNCY in Q4 2025 and has held it in 2 quarters since. The position peaked at $451K in Q4 2025. 51 funds tracked by Wall St. Rank hold UNCY as of Q1 2026.

  • OMERS Administration Corp held 31,900 shares of Unicycive Therapeutics worth $210K as of Q1 2026.
  • OMERS Administration Corp sold 46,300 Unicycive Therapeutics shares in Q1 2026, an estimated $303K.
  • Unicycive Therapeutics made up ﹤0.01% of OMERS Administration Corp's portfolio in Q1 2026, its #913 holding.
  • OMERS Administration Corp first reported a position in Unicycive Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • OMERS Administration Corp's Unicycive Therapeutics position peaked at $451K in Q4 2025.
  • 51 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q1 2026.

Based on OMERS Administration Corp's 13F filing for Q1 2026, filed 15 May 2026.